Pembrolizumab benefits a minority of heavily pretreated patients with advanced metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, according to an open-label phase 2 trial.
https://www.journalofclinicalpathways.com/news/pembrolizumab-shows-modest-activity-advanced-esophageal-cancer
Pembrolizumab shows modest activity in advanced esophageal cancer